# Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

> **NCT03769103** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **British Columbia Cancer Agency** · enrollment: 40 (actual)

## Conditions studied

- Lung Cancer Non-small Cell Stage IV
- Brain Metastases

## Interventions

- **DRUG:** Osimertinib
- **RADIATION:** Stereotactic radiotherapy

## Key facts

- **NCT ID:** NCT03769103
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-19
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03769103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03769103, "Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03769103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*